Li Shuang-Long, Zhang Yi, Cheng Qian-Shi, Xin Jun-Zhe, Dong Ze-Qin, Qiu Xiang-Jun
School of Basic Medicine, Henan University of Science and Technology, Luoyang 471023, People's Republic of China.
Infect Drug Resist. 2020 Sep 14;13:3153-3161. doi: 10.2147/IDR.S269831. eCollection 2020.
An ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for the determination of selinexor was established to investigate the effects of isavuconazole, itraconazole and fluconazole on the pharmacokinetics of selinexor in rats, respectively.
Twenty-four healthy male rats were randomly divided into four groups: group A, normal saline; group B, isavuconazole (20 mg/kg); group C, itraconazole (20 mg/kg); and group D, fluconazole (20 mg/kg). After 30 min of oral administration of normal saline, isavuconazole, itraconazole, and fluconazole, all the rats were given selinexor (8 mg/kg). The plasma concentration of selinexor was estimated by UPLC-MS/MS, and the pharmacokinetic parameters of selinexor were calculated by Drug and Statistics (DAS) 2.0 software.
Under these experimental conditions, the method showed good linearity and stability. Intraday and interday accuracy and sample recovery were acceptable. Compared with group A, the C, AUC and AUC of selinexor in group B increased by 59.05%, 31.69%, and 31.45%; the C, AUC and AUC of selinexor in group C increased by 56.14%, 25.34%, and 25.08%; the C, AUC and AUC of selinexor in group D increased by 43.44%, 29.16%, and 31.96%, respectively. The T of the experimental groups were extended, and CLz/F was also significantly reduced.
These results indicated that isavuconazole, itraconazole, and fluconazole have significant inhibitory effects on selinexor pharmacokinetics and increased selinexor plasma exposure in rats. Therefore, when these drugs were used in combination, clinicians should pay attention to the changes in treatment effects and the occurrence of adverse reactions caused by the drug-drug interactions.
建立一种超高效液相色谱串联质谱法(UPLC-MS/MS)测定塞利尼索,以分别研究艾沙康唑、伊曲康唑和氟康唑对大鼠体内塞利尼索药代动力学的影响。
将24只健康雄性大鼠随机分为四组:A组,生理盐水;B组,艾沙康唑(20mg/kg);C组,伊曲康唑(20mg/kg);D组,氟康唑(20mg/kg)。口服生理盐水、艾沙康唑、伊曲康唑和氟康唑30分钟后,所有大鼠均给予塞利尼索(8mg/kg)。采用UPLC-MS/MS测定塞利尼索的血浆浓度,并通过药物与统计学(DAS)2.0软件计算塞利尼索的药代动力学参数。
在这些实验条件下,该方法显示出良好的线性和稳定性。日内和日间精密度以及样品回收率均可接受。与A组相比,B组塞利尼索的Cmax、AUC0-t和AUC0-∞分别增加了59.05%、31.69%和31.45%;C组塞利尼索的Cmax、AUC0-t和AUC0-∞分别增加了56.14%、25.34%和25.08%;D组塞利尼索的Cmax、AUC0-t和AUC0-∞分别增加了43.44%、29.16%和31.96%。各实验组的T1/2延长,CLz/F也显著降低。
这些结果表明,艾沙康唑、伊曲康唑和氟康唑对塞利尼索的药代动力学有显著抑制作用,并增加了大鼠体内塞利尼索的血浆暴露量。因此,当联合使用这些药物时,临床医生应注意治疗效果的变化以及药物相互作用引起的不良反应的发生。